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ABSTRACT
Objectives: The aim of the study was to determine whether anhydramnios affected the duration of medical abortion in 
cases with various indications as compared to cases with normal amniotic fluid volume. 
Material and methods: Patients who were admitted to our clinic because of medical abortion between January 2010–De-
cember 2013 were included in this retrospective study. A total of 32 pregnant women with anhydramnios (study group) 
and 67 pregnant women with normal amniotic fluid volume but with fetal abnormality (control group) were included in the 
study. Patient age, gravidity, parity, gestational age, previous delivery route, and duration of the abortion were recorded. 
Results: Mean duration of the abortion in the study group was 71.93 ± 47.51 h as compared to 79.08 ± 52.62 h in the control 
group. There were no statistically significant differences between the two groups in terms of duration of the abortion (p = 0.516). 
Also, we found no statistically significant differences in duration of the abortion with regard to previous delivery route (p = 0.220). 
Conclusions: There were no statistically significant differences between the study group and controls in terms of duration 
of the abortion. In addition, neither parity nor previous delivery route affected the duration of the abortion. 
Key words: medical abortion, anhydramnios, duration of abortus
Ginekologia Polska 2016; 87, 9: 635–638
Corresponding author:
Oya Soylu Karapinar
Ürgenpaşa Mahallesi, 41. Sokak, Esen Apartmanı, Daire 7, Antakya, Hatay, Turkey
tel.: 0 505 502 51 48, e-mail: oyakarapinar@hotmail.com
INTRODUCTION
Termination of pregnancy (TOP) remains one of the most 
common procedures in obstetrics and gynecology, with the 
estimated 50 million induced abortions each year world-
wide [1]. Furthermore, due to the introduction of successful 
large-scale antenatal screening programs for the detection 
of chromosomal abnormalities and major structural fetal 
malformations, first and second-trimester abortions are 
also on the rise [2, 3]. 
There are cases which require medical abortion due to 
severe structural malformations, genetic disorders, and in-
trauterine fetal demise. In these cases, prostaglandin (miso- 
prostol) is administered. The use of misoprostol, a synthetic 
15-deoxy-16-hydroxy-16-methyl analog of the naturally oc-
curring prostaglandin E1, for termination of pregnancy (TOP) 
was first described in 1994 [4]. Since then, this agent has been 
widely used for pregnancy termination due to its low cost, 
effectiveness, and drug stability at ambient temperature [5], 
as well as the fact that it can be readily used in several ways, 
such as sublingual, rectal, vaginal and oral routes. Also, his-
tory of cesarean section does not contraindicate the use of 
misoprostol [6], but caution and lower dose of misoprostol 
is required due to elevated risk of uterine rupture, regardless 
of gestational age [7]. The mode of administration, type, and 
dosage of misoprostol can lead to differences in induction 
to abortion time interval [8]. Furthermore, factors such as 
previous cesarean section, increasing gestational age, nul-
liparity, and amniotic fluid volume can influence the duration 
of a medical abortion [9]. In this retrospective study, we aimed 
to determine whether anhydramnios affected the duration 
of the abortion in case of medical abortion with various in-
dications, and compare it with cases with normal amniotic 
fluid, as well as to investigate whether previous history of 
cesarean section impacted the delay of the abortion.
MATERIAL AND METHODS
This retrospective study was conducted at the Depart-
ment of Obstetrics and Gynecology, Mustafa Kemal Univer-
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sity Hospital in Hatay, Turkey. Patients who were admitted to 
our clinic and deemed eligible for medical abortion between 
January 2010–December 2013 were included in the study. 
The study group consisted of 32 pregnant women with 
anhydramnios and the control group included 67 pregnant 
women who had normal amniotic fluid volume with various 
anomalies. The abortus indications for the abortion of the 
control group were as follows: spina bifida, hydrocepha-
lus, encephalocele, anencephaly, hydrops fetalis, multiple 
anomalies, heart anomalies (hypoplastic left heart), down 
syndrome, Beta thalassemia, sickle cell anemia and cystic 
hygroma, and fetal demise. Age, gravidity, parity, gestational 
age, obstetric history, indications for abortion, duration of 
abortus of the patients were recorded. Multiple pregnan-
cies were excluded from the study. Local Ethics Committee 
approved of the study. All participants gave their written 
informed consent for the study and pregnancy termination.
The method used for termination of pregnancy was 
chosen with respect to the history of previous cesarean sec-
tion. Misoprostol was used for medical abortion as: 200 μg 
p.o. and 200 μg vaginally twice a day in patients who had 
a history of cesarean section, and 200 μg p.o. and 200 μg 
vaginally thrice a day in patients who had a history of vaginal 
birth and nulliparity. We used a lower dose misoprostol in 
patients who had previous cesarean section due to the risk 
of uterine rupture. After medical abortion, routine revision 
curettage was not performed. Spontaneous expulsion of the 
placenta was awaited for up to 60 min. Digital examination 
and curettage were reserved for cases in which expulsion did 
not occur or was incomplete on the basis of clinical and/or 
sonographic findings.
Statistical analysis
Values shown in the text and the tables are mean ± SD. 
Statistical analysis was performed using the SPSS (Statistical 
Package for the Social Sciences) 21.0 Evaluation for Win-
dows. Student T test was used for the analysis between the 
anhydramnios and the control groups to measure baseline 
characteristics such as age, parity, gestational age, and dura-
tion of abortion. Correlations between the cesarean section, 
vaginal birth and nulliparity were assessed by one-way 
and ANOVA tests. The p-value of < 0.05 was considered as 
statistically significant.
RESULTS 
Between 2010–2013, 99 women underwent a medi-
cal termination for a prenatally recognized anhydramnios 
and fetal abnormality, with normal amniotic fluid volume, 
between 10 and 27 weeks of gestation in our clinic. Out of 
these, 32 (32.3%) patients had anhydramnios (study group) 
and 67 (67.7%) had some anomalies with normal amniotic 
fluid (control group). Mean patient age was 28.10 ± 5.72 
(15–41) and mean gestational age was 17.94 ± 3.40 (10–27) 
weeks. Sixty-one (61.6%) patients had previous vaginal 
delivery, 28 (28.3%) had previous cesarean section, and 
10 (10.1%) patients were nulliparous. Mean gravidity was 
2.68 (± 1.33) (minimum 1–maximum 6) and 2.43 (± 0.85) 
(minimum 1–maximum 5) in the anhydramnios group and 
in the control group, respectively. There were 5 (15.6%) pri-
migravidas in the anhydramnios group and 5 primigravidas 
(7.5%) in the control group. Demographic data of the study 
and control group patients are presented in Table 1.
Mean duration of the abortion was 71.93 ± 47.51 h and 
79.08 ± 52.62 h in in the anhydramnios group and the con-
trol group, respectively. There were no statistically significant 
differences between the two groups in terms of duration 
of the abortion (p = 0.516). If we compare both groups 
with regard to the necessity of post-abortion curettage, 
21 patients (65.6%) in anhydramnios group and 57 patients 
(85.1%) in the control group required revision curettage. 
There was a statistically significant difference between both 
groups as far as the need for revision curettage is concerned 
(p = 0.028). The anhydramnios group required revision curet-
tage less often than the control group. 
Mean duration of the abortion was 69.95 ± 31.24 h in 
patients with a history of vaginal birth, and 87.07 ± 74.38 h 
in patients with a history of cesarean section. Primigravidas 
had mean duration of the abortion of 91.77 ± 68.06 h. There 
were no statistically significant differences in duration of the 
abortion with regard to obstetric history (p = 0.220).
Table 1. Demographic data and duration of the abortion in the study group and controls 
Study group  
(anhydramnios)
n = 32
Control group  
(normal amniotic fluid volume)
n = 67
p
Maternal age 29.0 (± 6.52) 27.6 (± 5.29) 0.282
Gravidity 2.68 (± 1.33) 2.43 (± 0.85) 0.254
Parity 2.31 (± 1.65) 2.14 (± 1.15) 0.893
Gestational age at termination (week) 19.7 (± 2.9) 17.08 (± 3.29) 0.0001
Duration of abortion (hour) 71.93 (± 47.51) 79.08 (± 52.62) 0.516
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DISCUSSION
Prenatal screening is a fundamental component of mod-
ern obstetric practice and has enabled millions of women 
to progress through a pregnancy with confidence with re-
gard to the structural integrity of their fetus. On occasion, 
however, a significant fetal abnormality will be diagnosed 
and some women will elect to interrupt the pregnancy fol-
lowing counseling about the potential outcomes of such 
a decision [10]. TOP in the second trimester constitutes 
about 10–15% of all pregnancies and most TOPs due to fetal 
abnormalities occur after the first trimester of pregnancy. 
Various mechanical and pharmacological techniques have 
been attempted, including laminaria, Foley balloon traction, 
and prostaglandin analogs. Prostaglandins are the mainstay 
of medical terminations over 13 weeks of gestation, either 
as a single drug or combined with mifepristone [10, 11]. 
Misoprostol has been applied in different doses and routes 
for the second trimester TOP [12]. Various doses have been 
used, ranging from 200 to 800 μg at intervals ranging from 
3 to 12 h [13–15]. Doses of 600 and 800 μg had comparable 
effects on the abortion rates, but are associated with high-
er incidence of fever, diarrhea, nausea, and vomiting [16]. 
Vaginal administration of misoprostol is more effective 
than other routes of administration and the incidence of 
side effects is lower [17–18].
Although many studies on the effectiveness and pos-
sible complications of misoprostol use for pregnancy ter-
mination in a normal uterus have been published, few have 
addressed the specific subject of the scarred uterus due to 
cesarean section using misoprostol as the single abortifa-
cient agent [19–21]. History of cesarean section does not 
contraindicate the use of misoprostol [6], but caution and 
lower dose of misoprostol are required due to the higher 
risk of uterine rupture, regardless of gestational age [7]. 
There are little data available regarding the optimal dosage 
of misoprostol in second-trimester pregnancy terminations 
in women with previous caesarian sections [22]. Therefore, 
misoprostol was used for medical abortion as: 200 μg p.o. 
and 200 μg vaginally twice a day in patients with a history 
of cesarean section, and 200 μg p.o. and 200 μg vaginally 
thrice a day in patients with a history of vaginal birth and 
nulliparity. Notably, mean dose of misoprostol necessary to 
induce an abortion was lower in the cesarean group as com-
pared to the vaginal birth group and nulliparous patients. As 
reported in other studies [23, 24], we observed no statistical 
differences between the cesarean and the vaginal birth 
groups in the delay between induction and abortion, and 
in particular in the duration of the abortion. The lower dose 
of misoprostol used in the group of women with a history 
of cesarean section did not impact the delay to abortion 
significantly. This is important since prolonged induction 
of labor up to 24 h has been correlated with a higher risk of 
uterine rupture [25]. Furthermore, we found no statistical 
differences between nulliparous patients and cesarean and 
vaginal birth (multiparous women) groups in the duration 
of abortion. Median duration of the abortion was reduced 
by 25% in multiparous women as compared to nulliparous 
women, which may be attributed to the faster ripening of 
the cervix after a previous spontaneous delivery [26]. A cor-
relation between obstetric history was also observed by Jan-
net et al. In their study, which consisted of 106 terminations 
of pregnancy with a combination of 600 mg mifepristone 
and 400 μg misoprostol, the time interval between the first 
induction and fetal expulsion was significantly shorter in 
multiparous than in primiparous women [27]. In a study by 
Wagner, the time interval was prolonged in case of previous 
cesarean section and nulliparity as compared to previous 
spontaneous delivery [9]. In contrast, in our study parity and 
previous delivery route did not seem to affect the duration 
of the abortion. 
Factors determining the duration of second trimester 
pregnancy termination were evaluated by various authors, 
but the effect of anhydramnios has not yet been clarified. 
For example, there were three main factors which influ-
enced the duration of the abortion in a study by Dickinson 
and Doherty. Increasing gestational age, nulliparity, and 
advanced maternal age were associated with prolongation 
of the abortion [28]. In the study by Wagner, the parameters 
with significant influence were gestational age at the time of 
induction, obstetric history, and nulliparity. Similarly to these 
two studies, Norbert et al., observed a prolonged induction 
time with increasing gestational age and attributed this to 
the need for greater cervical dilatation due to the increasing 
fetal size. It could therefore be argued that the prolonged 
induction interval with gestational age could be due a re-
duction of the receptivity of the uterus to prostaglandins [9]. 
Multiparous women responded to the vaginal misoprostol 
with a shorter induction–delivery interval than nulliparous 
women, a phenomenon also observed by prior studies us-
ing pretreatment with mifepristone [26, 29]. This can be 
attributed to the faster ripening of the cervix after a previ-
ous spontaneous delivery. A longer time interval in women 
with a previous caesarean section in the study of Wagner 
could be due to the absence of a previous spontaneous 
delivery [9]. In the study by Dickinson, higher maternal age 
was associated with an increased requirement for surgical 
intervention, which is consistent with the reports of Ashok 
et al. [28]. Sak et al., studied the factors influencing the 
duration of misoprostol-induced abortion in the second 
trimester and found the induction-to-abortion interval to 
be longer in patients with hyperglycemia and advanced 
gestational age [30]. 
Only in one study, patients who received prostaglandins 
for termination classified according to the amniotic fluid 
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volume (normal, polyhydramnios, and oligohydramnios). 
In that study, no significant differences were found about 
the median time interval between the first induction and 
expulsion in the three groups [9]. In our study, anhydramnios 
did not affect the duration of the abortion as compared to 
patients with normal amniotic fluid volume. To the best of 
our knowledge, this study has been the first to evaluate the 
effect of anhydramnios in the second trimester pregnancy 
termination.
CONCLUSIONS
The presence of anhydramnios in the second trimester 
termination does not affect the duration of the abortion. In 
addition, neither parity nor previous delivery route influence 
the duration of the abortion. 
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